UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
x
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
For the quarterly period ended June 30, 2010.
Or
¨
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
For the transition period from
to
.
Commission File Number 000-51171
COMBINATORX,
INCORPORATED
(Exact name of registrant as specified in its charter)
|
|
|
Delaware
|
|
04-3514457
|
(State or other jurisdiction of
Incorporation or organization)
|
|
(IRS Employer
Identification Number)
|
|
|
245 First Street
Third Floor
Cambridge, Massachusetts
|
|
02142
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
(617)
301-7000
(Registrants telephone number, including area code)
None
(Former name, former address and former fiscal year, if changes since last report)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90
days. Yes
x
No
¨
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every
Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such
files). Yes
¨
No
¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller
reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act.
|
|
|
|
|
|
|
|
|
|
|
Large accelerated filer
|
|
¨
|
|
|
|
|
Accelerated filer
|
|
¨
|
|
|
|
|
|
|
Non-accelerated filer
|
|
¨
|
|
|
|
|
Smaller reporting company
|
|
x
|
|
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange
Act). Yes
¨
No
x
Number of shares of the registrants Common Stock, $0.001 par value per share, outstanding as of August 9, 2010: 89,029,920
shares
COMBINATORX, INCORPORATED
QUARTERLY REPORT
ON FORM 10-Q
INDEX
2
PART I
FORWARD-LOOKING STATEMENTS
This quarterly report on Form 10-Q includes statements with respect to CombinatoRx, Incorporated (CombinatoRx) and its
subsidiaries (we, our or us), which constitute forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Words
such as believe, anticipate, expect, estimate, intend, plan, project, will be, will continue, will result, seek,
could, may, might, or any variations of such words or other words with similar meanings are intended to identify such forward-looking statements. Forward-looking statements in this quarterly report on Form 10-Q
include, without limitation, statements regarding our future expectations; any projections of financing needs, revenue, expenses, earnings or losses from operations, or other financial items; any statements of the plans, strategies and objectives of
management for future operations; any statements concerning product candidate research, development and commercialization plans and timelines; any statements regarding safety and efficacy of product candidates; any statements regarding plans for
outlicensing of our clinical or preclinical product candidates and seeking collaborations; any statements regarding timing of initiating and completing clinical and preclinical trials and studies; any statements of expectation or belief; and any
statements regarding other matters that involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to differ materially from results expressed in or implied by this
quarterly report on Form 10-Q.
The risks, uncertainties and assumptions referred to above include risks that are described in
the Risk Factors section if our annual report on Form 10-K and in our other Securities and Exchange Commission reports. You are cautioned not to place undue reliance on the forward-looking statements contained herein, which speak only as of the date
of this quarterly report on Form 10-Q. We specifically disclaim any obligation to update these forward-looking statements in the future, except as required by law.
Item 1.
|
Financial StatementsUnaudited
|
The financial information set forth below should be read in conjunction with our Managements Discussion and Analysis of
Financial Condition and Results of Operations appearing elsewhere in this Quarterly Report on Form 10-Q.
3
CombinatoRx, Incorporated
Condensed Consolidated Balance Sheets
(in thousands, except per share data)
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
June 30,
2010
|
|
|
December 31,
2009
|
|
Assets
|
|
|
|
|
|
|
|
|
Current assets:
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
2,175
|
|
|
$
|
8,779
|
|
Restricted cash
|
|
|
750
|
|
|
|
750
|
|
Short-term investments
|
|
|
47,498
|
|
|
|
14,551
|
|
Accounts receivable
|
|
|
2,249
|
|
|
|
2,927
|
|
Prepaid expenses and other current assets
|
|
|
1,335
|
|
|
|
5,415
|
|
|
|
|
|
|
|
|
|
|
Total current assets
|
|
|
54,007
|
|
|
|
32,422
|
|
Property and equipment, net
|
|
|
7,506
|
|
|
|
8,380
|
|
Intangible asset, net
|
|
|
36,055
|
|
|
|
45,423
|
|
Restricted cash and other assets
|
|
|
1,818
|
|
|
|
1,927
|
|
|
|
|
|
|
|
|
|
|
Total assets
|
|
$
|
99,386
|
|
|
$
|
88,152
|
|
|
|
|
|
|
|
|
|
|
Liabilities and stockholders equity
|
|
|
|
|
|
|
|
|
Current liabilities:
|
|
|
|
|
|
|
|
|
Accounts payable
|
|
$
|
1,094
|
|
|
$
|
4,269
|
|
Accrued expenses
|
|
|
2,342
|
|
|
|
5,495
|
|
Accrued restructuring
|
|
|
521
|
|
|
|
1,274
|
|
Deferred revenue
|
|
|
2,250
|
|
|
|
2,750
|
|
Current portion of lease incentive obligation
|
|
|
284
|
|
|
|
284
|
|
|
|
|
|
|
|
|
|
|
Total current liabilities
|
|
|
6,491
|
|
|
|
14,072
|
|
|
|
|
Deferred revenue, net of current portion
|
|
|
3,167
|
|
|
|
2,667
|
|
Deferred rent, net of current portion
|
|
|
759
|
|
|
|
775
|
|
Lease incentive obligation, net of current portion
|
|
|
1,584
|
|
|
|
1,726
|
|
Other long-term liabilities
|
|
|
2,103
|
|
|
|
3,235
|
|
Contingent consideration
|
|
|
|
|
|
|
12,764
|
|
|
|
|
Stockholders equity:
|
|
|
|
|
|
|
|
|
Preferred stock, $0.001 par value; 5,000 shares authorized; no shares issued and outstanding
|
|
|
|
|
|
|
|
|
Common stock, $0.001 par value; 200,000 shares authorized; 89,020 and 117,828 shares issued and outstanding at June 30, 2010
and December 31, 2009, respectively
|
|
|
89
|
|
|
|
118
|
|
Additional paid-in capital
|
|
|
316,485
|
|
|
|
272,405
|
|
Accumulated other comprehensive income (loss)
|
|
|
22
|
|
|
|
(2
|
)
|
Accumulated deficit
|
|
|
(231,314
|
)
|
|
|
(219,608
|
)
|
|
|
|
|
|
|
|
|
|
Stockholders equity
|
|
|
85,282
|
|
|
|
52,913
|
|
|
|
|
|
|
|
|
|
|
Total liabilities and stockholders equity
|
|
$
|
99,386
|
|
|
$
|
88,152
|
|
|
|
|
|
|
|
|
|
|
4
CombinatoRx, Incorporated
Condensed Consolidated Statements of Operations
(in thousands, except share and per share amounts)
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended June 30,
|
|
|
Six months ended June 30,
|
|
|
|
2010
|
|
|
2009
|
|
|
2010
|
|
|
2009
|
|
Revenue:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Collaborations and other
|
|
$
|
2,717
|
|
|
$
|
3,005
|
|
|
$
|
43,782
|
|
|
$
|
5,334
|
|
Government contracts and grants
|
|
|
211
|
|
|
|
313
|
|
|
|
476
|
|
|
|
617
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenue
|
|
|
2,928
|
|
|
|
3,318
|
|
|
|
44,258
|
|
|
|
5,951
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development
|
|
|
4,617
|
|
|
|
6,106
|
|
|
|
11,998
|
|
|
|
13,243
|
|
General and administrative
|
|
|
2,569
|
|
|
|
4,824
|
|
|
|
6,431
|
|
|
|
8,471
|
|
Amortization of intangible
|
|
|
4,685
|
|
|
|
|
|
|
|
9,369
|
|
|
|
|
|
Restructuring
|
|
|
|
|
|
|
(425
|
)
|
|
|
|
|
|
|
16
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total operating expenses
|
|
|
11,871
|
|
|
|
10,505
|
|
|
|
27,798
|
|
|
|
21,730
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Loss) income from operations
|
|
|
(8,943
|
)
|
|
|
(7,187
|
)
|
|
|
16,460
|
|
|
|
(15,779
|
)
|
Interest income
|
|
|
30
|
|
|
|
60
|
|
|
|
37
|
|
|
|
188
|
|
Interest expense
|
|
|
|
|
|
|
(11
|
)
|
|
|
|
|
|
|
(27
|
)
|
Loss on revaluation of contingent consideration
|
|
|
|
|
|
|
|
|
|
|
(29,286
|
)
|
|
|
|
|
Other income (expense)
|
|
|
15
|
|
|
|
(11
|
)
|
|
|
(127
|
)
|
|
|
(7
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss before provision for income taxes
|
|
|
(8,898
|
)
|
|
|
(7,149
|
)
|
|
|
(12,916
|
)
|
|
|
(15,625
|
)
|
Income tax benefit
|
|
|
300
|
|
|
|
|
|
|
|
1,210
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss from continuing operations
|
|
|
(8,598
|
)
|
|
|
(7,149
|
)
|
|
|
(11,706
|
)
|
|
|
(15,625
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Discontinued operations:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from discontinued operations
|
|
|
|
|
|
|
(529
|
)
|
|
|
|
|
|
|
(1,536
|
)
|
Gain on disposal of discontinued subsidiary
|
|
|
|
|
|
|
15,640
|
|
|
|
|
|
|
|
15,640
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gain on discontinued operations
|
|
|
|
|
|
|
15,111
|
|
|
|
|
|
|
|
14,104
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net (loss) income
|
|
$
|
(8,598
|
)
|
|
$
|
7,962
|
|
|
$
|
(11,706
|
)
|
|
$
|
(1,521
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net (loss) income per sharebasic and diluted:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
From continuing operations
|
|
$
|
(0.10
|
)
|
|
$
|
(0.20
|
)
|
|
$
|
(0.15
|
)
|
|
$
|
(0.44
|
)
|
From discontinued operations
|
|
|
|
|
|
|
0.43
|
|
|
|
|
|
|
|
0.40
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net (loss) income per sharebasic and diluted
|
|
$
|
(0.10
|
)
|
|
$
|
0.23
|
|
|
$
|
(0.15
|
)
|
|
$
|
(0.04
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average number of common shares used in net (loss) income per share calculationbasic and diluted
|
|
|
88,946,220
|
|
|
|
35,026,106
|
|
|
|
76,199,264
|
|
|
|
35,019,779
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5
CombinatoRx, Incorporated
Condensed Consolidated Statements of Cash Flow
(in thousands)
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended June 30
|
|
|
|
2010
|
|
|
2009
|
|
Operating activities
|
|
|
|
|
|
|
|
|
Net loss
|
|
$
|
(11,706
|
)
|
|
$
|
(1,521
|
)
|
Less: Net loss from discontinued operations
|
|
|
|
|
|
|
(1,536
|
)
|
Gain on disposal of discontinued operations
|
|
|
|
|
|
|
15,640
|
|
|
|
|
|
|
|
|
|
|
Loss from continuing operations
|
|
|
(11,706
|
)
|
|
|
(15,625
|
)
|
Adjustments to reconcile loss from continuing operations to net cash provided by (used in) operating activities from continuing
operations:
|
|
|
|
|
|
|
|
|
Depreciation
|
|
|
1,241
|
|
|
|
2,608
|
|
Amortization of intangible
|
|
|
9,369
|
|
|
|
|
|
Noncash interest expense
|
|
|
|
|
|
|
27
|
|
Noncash rent expense
|
|
|
(142
|
)
|
|
|
(287
|
)
|
Stock-based compensation expense
|
|
|
2,005
|
|
|
|
2,459
|
|
Loss on revaluation of contingent consideration
|
|
|
29,286
|
|
|
|
|
|
Loss on sale of fixed assets
|
|
|
52
|
|
|
|
47
|
|
Foreign exchange loss
|
|
|
50
|
|
|
|
|
|
Decrease in deferred rent
|
|
|
(16
|
)
|
|
|
(21
|
)
|
Changes in assets and liabilities:
|
|
|
|
|
|
|
|
|
Decrease in accounts receivable
|
|
|
678
|
|
|
|
361
|
|
Decrease (increase) in prepaid expenses and other assets
|
|
|
4,189
|
|
|
|
(23
|
)
|
Decrease in accounts payable
|
|
|
(3,175
|
)
|
|
|
(1,548
|
)
|
Decrease in accrued restructuring
|
|
|
(753
|
)
|
|
|
(2,224
|
)
|
(Decrease) increase in accrued expenses and other long-term liabilities
|
|
|
(4,343
|
)
|
|
|
79
|
|
Increase in deferred revenue
|
|
|
|
|
|
|
955
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by (used in) operating activities from continuing operations
|
|
|
26,735
|
|
|
|
(13,192
|
)
|
Net cash used in operating activities from discontinued operations
|
|
|
|
|
|
|
(1,088
|
)
|
|
|
|
|
|
|
|
|
|
Net cash provided by (used in) operating activities
|
|
|
26,735
|
|
|
|
(14,280
|
)
|
|
|
|
|
|
|
|
|
|
Investing activities
|
|
|
|
|
|
|
|
|
Purchases of property and equipment
|
|
|
(517
|
)
|
|
|
(37
|
)
|
Proceeds from sale of property and equipment
|
|
|
97
|
|
|
|
142
|
|
Loss from sale of equity interest in subsidiary
|
|
|
|
|
|
|
(6,240
|
)
|
Purchases of short-term investments
|
|
|
(261,635
|
)
|
|
|
(61,207
|
)
|
Sales and maturities of short-term investments
|
|
|
228,712
|
|
|
|
76,536
|
|
|
|
|
|
|
|
|
|
|
Net cash (used in) provided by investing activities from continuing operations
|
|
|
(33,343
|
)
|
|
|
9,194
|
|
Net cash used in investing activities from discontinued operations
|
|
|
|
|
|
|
(16
|
)
|
|
|
|
|
|
|
|
|
|
Net cash (used in) provided by investing activities
|
|
|
(33,343
|
)
|
|
|
9,178
|
|
|
|
|
|
|
|
|
|
|
Financing activities
|
|
|
|
|
|
|
|
|
Proceeds from exercise of stock options
|
|
|
386
|
|
|
|
2
|
|
Repurchases of common stock
|
|
|
(391
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash (used in) provided by financing activities from continuing operations
|
|
|
(5
|
)
|
|
|
2
|
|
|
|
|
|
|
|
|
|
|
Effect of exchange rate changes on cash and cash equivalents
|
|
|
9
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net decrease in cash and cash equivalents
|
|
|
(6,604
|
)
|
|
|
(5,100
|
)
|
Cash and cash equivalents at beginning of the
period
|
|
|
8,779
|
|
|
|
10,380
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents at end of the
period
|
|
$
|
2,175
|
|
|
$
|
5,280
|
|
|
|
|
|
|
|
|
|
|
6
CombinatoRx, Incorporated
Notes to Condensed Consolidated Financial Statements
(all dollar amounts are in thousands, except per share amounts)
(Unaudited)
1. Basis
of Presentation
The accompanying unaudited condensed consolidated financial statements of CombinatoRx, Incorporated (the
Company) have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) for interim financial reporting and as required by Regulation S-X, Rule 10-01. Accordingly, they do not
include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (including those which are normal and recurring) considered necessary for a fair presentation of the
interim financial information have been included. When preparing financial statements in conformity with GAAP, the Company must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and related
disclosures at the date of the financial statements. Actual results could differ from those estimates. Additionally, operating results for the six months ended June 30, 2010 are not necessarily indicative of the results that may be expected for
any other interim period or for the fiscal year ending December 31, 2010. For further information, refer to the financial statements and footnotes included in the Companys Annual Report on Form 10-K for the year ended
December 31, 2009 as filed with the Securities and Exchange Commission (SEC) on March 26, 2010.
In preparing the
financial statements included in this Form 10-Q, the Company has evaluated all subsequent events that occurred after June 30, 2010 through the date of the filing of this Form 10-Q. The Company did not have any material recognizable or
unrecognizable subsequent events during this period.
2. Recent Accounting Pronouncements
In October 2009, the Financial Accounting Standards Board, or FASB, issued guidance which amends existing revenue recognition accounting pronouncements
and provides accounting principles and application guidance on the accounting for multiple element arrangements, including whether multiple deliverables exist, how the arrangement should be separated, and the consideration allocated. This guidance
eliminates the requirement to establish the fair value of undelivered products and services and instead provides for separate revenue recognition based upon managements estimate of the selling price for an undelivered item when there is no
other means to determine the fair value of that undelivered item. Previous accounting principles required that the fair value of the undelivered item be the price of the item either sold in a separate transaction between unrelated third parties or
the price charged for each item when the item is sold separately by the vendor. This was difficult to determine when the product was not individually sold because of its unique features. If the fair value of all of the elements in the arrangement
was not determinable, then revenue was deferred until all of the items were delivered or fair value was determined. This new approach is effective prospectively for revenue arrangements entered into or materially modified in fiscal years beginning
on or after June 15, 2010, which for the Company means no later than January 1, 2011. Early adoption is permitted; however, adoption of this guidance as of a date other than January 1, 2011, will require the Company to apply this
guidance retrospectively effective as of January 1, 2010 and will require disclosure of the effect of this guidance as applied to all previously reported interim periods in the fiscal year of adoption. While the Company does not expect the
adoption of this standard to have a material impact on its financial position and results of operations, this standard may impact the Company in the event it completes future transactions or modifies existing collaborative relationships.
In October 2009, FASB updated its guidance on software revenue recognition rules.
According to this update, tangible products containing
software components and non-software components that function together to deliver the tangible products essential functionality, are no longer within the scope of the software revenue guidance. This update requires that hardware components of
a tangible product containing software components always be excluded from the software revenue guidance. This update provides additional guidance on how to determine which software, if any, relating to the tangible product should be excluded from
the scope of the software revenue guidance. This update will be effective prospectively for revenue arrangements entered into or materially modified in fiscal years beginning on or after June 15, 2010, but early adoption is permitted. This
update must be adopted in the same period using the same transition method as indicated above in the update to revenue arrangements with multiple deliverables. The Company is in the process of evaluating the impact the adoption of this pronouncement
will have on the consolidated financial statements.
In January 2010, the FASB issued updated guidance to amend the disclosure requirements
related to recurring and nonrecurring fair value measurements. This update requires new disclosures on significant transfers of assets and liabilities between Level 1 and Level 2 of the fair value hierarchy (including the reasons for these
transfers) and the reasons for any transfers in or out of Level 3. This update also requires a reconciliation of recurring Level 3 measurements about purchases, sales, issuances and settlements on a gross basis. In addition to these new
disclosure requirements, this update clarifies certain existing disclosure requirements. For example, this update clarifies that reporting entities are required to provide fair value measurement disclosures for each class of assets and liabilities
rather
7
than each major category of assets and liabilities. This update also clarifies the requirement for entities to disclose information about both the valuation techniques and inputs used in
estimating Level 2 and Level 3 fair value measurements. This update became effective for the Company with the interim and annual reporting period beginning January 1, 2010, except for the requirement to provide the Level 3
activity of purchases, sales, issuances, and settlements on a gross basis, which will become effective for the Company with the interim and annual reporting period beginning January 1, 2011. The Company will not be required to provide the
amended disclosures for any previous periods presented for comparative purposes. Other than requiring additional disclosures, adoption of this update will not have a material effect on the Companys consolidated financial statements.
In March 2010, the FASB issued guidance related to the milestone method of revenue recognition, which will codify a method of revenue
recognition that has been common practice. Under this method, contingent consideration from research and development activities that is earned upon the achievement of a substantive milestone is recognized in its entirety in the period in which the
milestone is achieved. This guidance is effective for annual periods beginning on or after June 15, 2010 but may be adopted as of the beginning of an annual period. The Company has been accounting for milestones as codified with this new
guidance. Consequently there will be no effect on the Companys consolidated financial position, results of operations and cash flows.
3. Fair Value Disclosure
The Company
has certain financial assets and liabilities recorded at fair value which have been classified as Level 1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.
|
|
Level 1Quoted market prices in active markets for identical assets or liabilities. Assets utilizing Level 1 inputs include money market funds,
U.S. government securities and bank deposits;
|
|
|
Level 2Inputs other than Level 1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield
curves. Assets utilizing Level 2 inputs include U.S. agency securities, including direct issuance bonds and corporate bonds; and
|
|
|
Level 3Unobservable inputs developed using estimates and assumptions developed by the Company, which reflect those that a market participant
would use.
|
The following tables summarize the financial instruments measured at fair value on a recurring basis in the
accompanying consolidated balance sheet as of June 30, 2010:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair Value Measurement as of June 30, 2010
|
|
Total
|
|
|
Level 1
|
|
Level 2
|
|
Level 3
|
|
Assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-term investments
|
|
$
|
9,616
|
|
$
|
37,8822
|
|
$
|
|
|
$
|
47,498
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The Companys Level 2 securities are valued using third-party
pricing sources. These sources generally use interest rates and yield curves observable at commonly quoted intervals of similar assets as observable inputs for pricing.
As of December 31, 2009, the liability for contingent consideration was valued using managements estimates of the number of shares that would
be released to the former stockholders of Neuromed Pharmaceuticals Inc. (Neuromed) upon the outcome and related timing of FDA approval of Exalgo (see Note 6). The valuation was dependent on the Companys stock price and an
assessment of the final number of Escrow Shares (as defined below in Note 6) that were to be issued to former Neuromed stockholders. As such, this valuation was determined to be a Level 3 valuation, as the primary inputs were unobservable. On
March 1, 2010, the shares held in escrow were released to the former Neuromed stockholders upon the FDAs approval of Exalgo. The Company valued the liability prior to settlement using the closing stock price on March 1, 2010. This
valuation was a Level 1 valuation, as the Companys stock price is an observable input.
The following table provides a roll forward of
the fair value of the contingent consideration, where fair value is determined by Level 3 inputs:
|
|
|
|
|
Balance at January 1, 2010
|
|
$
|
12,764
|
|
Additions
|
|
|
|
|
Change in fair value
|
|
|
|
|
Transfer to Level 1 valuations
|
|
|
(12,764
|
)
|
|
|
|
|
|
Balance at March 1, 2010
|
|
$
|
|
|
|
|
|
|
|
8
4. Short-Term Investments
Short-term investments consist primarily of investments with original maturities greater than ninety days and less than one year when purchased. The
Company classifies these investments as available-for-sale. Unrealized gains and losses are included in other comprehensive income (loss).
Available-for-sale securities at June 30, 2010 and December 31, 2009 consist of the following:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortized
Cost
|
|
Unrealized
Gains
|
|
Unrealized
Losses
|
|
|
Fair
Value
|
June 30, 2010
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Corporate debt securities
|
|
$
|
33,865
|
|
$
|
23
|
|
$
|
(3
|
)
|
|
$
|
33,885
|
Government agency securities
|
|
|
3,995
|
|
|
2
|
|
|
|
|
|
|
3,997
|
Treasury money market funds
|
|
|
9,616
|
|
|
|
|
|
|
|
|
|
9,616
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
47,476
|
|
$
|
25
|
|
$
|
(3
|
)
|
|
$
|
47,498
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, 2009
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Government agency securities
|
|
$
|
7,845
|
|
$
|
|
|
$
|
(2
|
)
|
|
$
|
7,843
|
Treasury money market funds
|
|
|
6,708
|
|
|
|
|
|
|
|
|
|
6,708
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
14,553
|
|
$
|
|
|
$
|
(2
|
)
|
|
$
|
14,551
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The amortized cost and estimated fair value of investments in debt
securities, which excludes money market funds, at June 30, 2010 and December 31, 2009, by contractual maturity, were as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
June 30, 2010
|
|
December 31, 2009
|
|
|
Cost
|
|
Estimated
Fair Value
|
|
Cost
|
|
Estimated
Fair Value
|
Maturing in one year or less
|
|
$
|
37,860
|
|
$
|
37,882
|
|
$
|
7,845
|
|
$
|
7,843
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The cost of securities sold is determined based on the specific
identification method for purposes of recording realized gains and losses. Gross realized gains and losses on the sales of investments have not been material to the Companys results of operations for all periods presented. As a matter of
investment policy, the Company does not invest in auction rate securities.
5. Intangible Asset
The intangible asset relates to the commercial rights to the Exalgo contract that was acquired as part of the December 21, 2009 merger with Neuromed.
The intangible asset amount of $45,943 was recorded at fair value on the merger date. The merger date fair value was determined using the projected future cash flows associated with the commercial rights to Exalgo that were sold to Covidien in June
2009. The intangible asset is being amortized in a manner which reflects estimates of future undiscounted cash flows expected to be generated from Exalgo over an estimated useful life of five years, representing the estimated remaining patent life
of Exalgo. The Company recognized $9,369 and $0 of amortization expense for the six months ended June 30, 2010 and 2009, respectively, and $4,685 and $0 for the three months ended June 30, 2010 and 2009, respectively. The Company
continually monitors whether events or circumstances have occurred that indicate that the estimated remaining useful life of its intangible asset may warrant revision or that the carrying value of the asset may be impaired. As of June 30, 2010
and December 31, 2009, the Company concluded that the intangible asset was not impaired.
6. Contingent Consideration
On December 21, 2009, the Company completed the merger with Neuromed. Under the terms of the merger agreement and a related escrow agreement (the
Escrow Agreement), at closing the Company issued 14,937,654 new shares of its common stock (the Firm Shares) to Neuromed stockholders and placed 67,826,875 new shares in escrow for the benefit of Neuromed stockholders (the
Escrow Shares). Of the Escrow Shares subject to the Escrow Agreement, an aggregate of 19,916,872 shares (the Holdback Shares) were placed into escrow and would or would not be released to Neuromed stockholders depending upon
the timing of the FDAs approval of Exalgo and an aggregate of 47,910,003 shares (the Milestone Shares) were placed into escrow and would or would not be released to Neuromed stockholders depending upon the timing of the FDAs
approval of Exalgo. Former Neuromed stockholders had voting and other ownership rights with respect to the Holdback Shares but no voting rights with respect to the Milestone Shares. The release of the Escrow Shares, and any resulting adjustment of
the relative ownership percentage of the then outstanding shares of common stock of the combined company, was based upon the timing of the FDAs approval of Exalgo and, subject to the terms and conditions of the Escrow Agreement:
9
|
|
|
If FDA approval of Exalgo were received on or before December 31, 2009, all of the Escrow Shares would be released to the former Neuromed
stockholders, resulting in the pre-merger CombinatoRx stockholders owning approximately 30% of the then outstanding shares of common stock of the combined company.
|
|
|
|
If FDA approval of Exalgo were received on or after January 1, 2010 and on or before September 30, 2010, a portion of the Escrow Shares would
be released to the former Neuromed stockholders and a portion would be cancelled, resulting in the pre-merger CombinatoRx stockholders owning approximately 40% of the then outstanding shares of common stock of the combined company.
|
|
|
|
If FDA approval of Exalgo were received on or after October 1, 2010 and on or before December 31, 2010, a portion of the Escrow Shares would
be released to the former Neuromed stockholders and a portion would be cancelled, resulting in the pre-merger CombinatoRx stockholders owning approximately 60% of the then outstanding shares of common stock of the combined company.
|
|
|
|
If FDA approval of Exalgo were not received on or before December 31, 2010, all of the remaining Escrow Shares would be cancelled, resulting in
the pre-merger CombinatoRx stockholders owning approximately 70% of the then outstanding shares of common stock of the combined company.
|
Because the FDA did not approve Exalgo prior to January 1, 2010, 29,943,752 Escrow Shares were returned to the Company on January 1, 2010 and
were subsequently cancelled. The FDA approved Exalgo on March 1, 2010. As a result, 37,883,123 Escrow Shares were released to former Neuromed stockholders.
The Company had classified the fair value of contingent consideration of $12,764 as a long-term liability in the consolidated balance sheet as of
December 31, 2009. On March 1, 2010, the FDA approved the New Drug Application for Exalgo, and the contingency was resolved. The fair value of the contingent consideration liability was $42,050 as of March 1, 2010 and the Company
recorded a loss of $29,286 in the six months ended June 30, 2010. The fair value of the contingent consideration as of the resolution of the contingency was recorded as additional paid-in capital upon the release of the Escrow Shares.
7. Comprehensive (Loss) Income
The Companys total comprehensive (loss) income consists of the following:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended June 30,
|
|
Six months ended June 30,
|
|
|
|
2010
|
|
|
2009
|
|
2010
|
|
|
2009
|
|
Net (loss) income
|
|
$
|
(8,598
|
)
|
|
$
|
7,962
|
|
$
|
(11,706
|
)
|
|
$
|
(1,521
|
)
|
Other comprehensive (loss) income:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Unrealized gain (loss) on investments
|
|
|
22
|
|
|
|
|
|
|
24
|
|
|
|
(61
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive (loss) income
|
|
$
|
(8,576
|
)
|
|
$
|
7,962
|
|
$
|
(11,682
|
)
|
|
$
|
(1,582
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
8. Net Loss Per Share
Earnings per share information is determined using the two-class method, which includes the weighted-average number of common shares outstanding during
the period and other securities that participate in dividends (participating securities). The Company considered the Escrow Shares issued in connection with the Neuromed merger participating securities because they include
rights to participate in undistributed earnings of the Company in the form of dividends with the common stock on a one for one basis. Prior to being released from escrow, the Escrow Shares were not considered in the calculation of basic net loss per
share for the six months ended June 30, 2010 since they did not include a contractual obligation to share in the losses of the Company.
The following potentially dilutive securities outstanding prior to the use of the treasury stock method have been excluded from the computation of
diluted weighted-average shares outstanding as of June 30, 2010 and 2009, as they would be anti-dilutive.
|
|
|
|
|
|
|
Six Months Ended
June 30,
|
|
|
2010
|
|
2009
|
Options outstanding
|
|
7,076,296
|
|
5,299,669
|
Unvested restricted stock or restricted stock units
|
|
762,500
|
|
57,500
|
Warrants outstanding
|
|
96,252
|
|
96,252
|
9. Stock-Based Compensation
The Company recognized, for the three and six months ended June 30, 2010 and 2009, stock-based compensation expense of approximately $429
and $1,204 and $2,005 and $2,459, respectively, in connection with its stock-based payment awards.
10
Stock Plans
A summary of the status of the Companys stock option plans at June 30, 2010 and changes during the six months then ended is presented in the
table and narrative below:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options
|
|
|
Weighted-
Average
Exercise Price
|
|
Weighted-
Average
Remaining
Contractual
Term
|
|
Aggregate
Intrinsic Value
|
Outstanding at December 31, 2009
|
|
4,108,663
|
|
|
$
|
3.50
|
|
|
|
|
|
Granted
|
|
3,657,000
|
|
|
|
0.95
|
|
|
|
|
|
Exercised
|
|
(409,280
|
)
|
|
|
0.94
|
|
|
|
|
|
Cancelled
|
|
(280,087
|
)
|
|
|
3.43
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Outstanding at June 30, 2010
|
|
7,076,296
|
|
|
$
|
2.33
|
|
6.45
|
|
$
|
2,558
|
|
|
|
|
|
|
|
|
|
|
|
|
Vested or expected to vest at June 30, 2010
|
|
6,434,172
|
|
|
$
|
2.47
|
|
6.17
|
|
$
|
2,236
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercisable at June 30, 2010
|
|
2,789,227
|
|
|
$
|
4.43
|
|
2.33
|
|
$
|
418
|
|
|
|
|
|
|
|
|
|
|
|
|
The aggregate intrinsic value in the table above represents the value
(the difference between the Companys closing common stock price on the last trading day of the six months ended June 30, 2010 and the exercise price of the options, multiplied by the number of in-the-money options) that would have been
received by the option holders had all option holders exercised their options on June 30, 2010. As of June 30, 2010, there was $2,506 of total unrecognized stock-based compensation expense related to stock options granted under the plans.
The expense is expected to be recognized over a weighted-average period of 2.6 years.
The Company uses the Black-Scholes pricing model as it
is the most appropriate valuation method for its option grants. The Black-Scholes model requires inputs for risk-free interest rate, dividend yield, volatility and expected lives of the options. For options granted during the six months ended
June 30, 2010, the Company used the historical volatility of its stock price. The Company does not have sufficient history as a public company to evaluate the expected term of its option grants and has evaluated the expected term of several
peer companies in order to make a determination on the expected term of the option grants. The risk-free rate for periods within the expected term of the option is based on the United States Treasury yield curve in effect at the time of the grant.
The Company applies a forfeiture rate to all option grants to account for options not expected to vest. The forfeiture rate is determined based upon the Companys historical forfeitures of its option grants.
During the three and six months ended June 30, 2010 and 2009, respectively, the assumptions used in the Black-Scholes pricing model for new grants
were as follows. The Company did not issue any stock options during the three months ended June 30, 2009.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30,
|
|
Six Months Ended June 30,
|
|
|
|
2010
|
|
|
2009
|
|
2010
|
|
|
2009
|
|
Volatility factor
|
|
107.92
|
%
|
|
|
|
108.86
|
%
|
|
100.28
|
%
|
Risk-free interest rate
|
|
1.79
|
%
|
|
|
|
2.54
|
%
|
|
1.67
|
%
|
Dividend yield
|
|
|
|
|
|
|
|
|
|
|
|
Expected term (in years)
|
|
5.77
|
|
|
|
|
5.77
|
|
|
3.76
|
|
Restricted Stock
A summary of the status of non-vested restricted stock awards as of June 30, 2010 and changes during the six months ended
June 30, 2010 is as follows:
|
|
|
|
|
|
|
|
|
Restricted
Stock
|
|
|
Weighted-
Average Grant
Date Fair Value
|
Nonvested at December 31, 2009
|
|
18,750
|
|
|
$
|
4.57
|
Granted
|
|
|
|
|
|
|
Vested
|
|
(6,250
|
)
|
|
|
4.57
|
Canceled
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nonvested at June 30, 2010
|
|
12,500
|
|
|
$
|
4.57
|
|
|
|
|
|
|
|
As of June 30, 2010, there was $42 of total unrecognized
stock-based compensation expense related to non-vested restricted stock arrangements granted under the Amended and Restated 2004 Equity Incentive Plan (the 2004 Plan). The expense is expected to be recognized over a weighted-average
period of 1.6 years.
11
The Company issued performance-based Restricted Stock Units (RSUs) on December 21, 2009 and
January 15, 2010 to certain employees and directors. If the performance measure is not achieved, a portion of the vesting of the RSU grant is time based contingent upon the grantees continued employment or board membership with the
Company. The fair value of RSUs is based on the closing price of the Companys common stock on the award date. Expense for performance-based RSUs is recognized when it is probable the performance goal will be achieved. On March 1, 2010,
the performance goal for the December 21, 2009 RSU grants was achieved, and all corresponding expense, or $1,150, was recognized immediately as the awards vested in full. On March 1, 2010, the performance goal was achieved for the RSUs
granted on January 15, 2010 such that all of the awards are expected to ultimately vest. The expense for this grant will be recognized on a straight-line basis over the four year vesting period. Prior to December 21, 2009, the Company had
not granted awards of RSUs. A summary of the status of non-vested RSUs as of June 30, 2010 is as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Restricted Stock
Units
|
|
|
Weighted-
Average
Grant Date Fair
Value
|
|
Weighted
Average
Remaining
Contractual
Term
|
|
Aggregate
Intrinsic Value
|
Non-vested at December 31, 2009
|
|
1,077,976
|
|
|
$
|
1.07
|
|
|
|
|
|
Granted
|
|
750,000
|
|
|
|
0.95
|
|
|
|
|
|
Vested
|
|
(1,077,976
|
)
|
|
|
1.07
|
|
|
|
|
|
Cancelled
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-Vested at June 30, 2010
|
|
750,000
|
|
|
$
|
0.95
|
|
3.55
|
|
$
|
1,088
|
|
|
|
|
|
|
|
|
|
|
|
|
As of June 30, 2010, there was $516 of total unrecognized
stock-based compensation expense related to non-vested RSUs granted under the 2004 Plan. The expense is expected to be recognized over a weighted-average period of 3.6 years.
10. Restructuring
On July 1, 2009,
in connection with the entry into a merger agreement on June 30, 2009 with Neuromed, the Companys Board of Directors committed to a restructuring plan that resulted in a workforce reduction of 20 employees, or approximately 36% of the
Companys workforce. The restructuring was a result of a continued strategic realignment of the Company to focus its efforts on its funded drug discovery and on conserving capital in connection with the merger with Neuromed.
As a result of the July 1, 2009 restructuring plan, the Company recorded a restructuring charge of $2,597 in the third quarter of 2009, consisting
of termination benefits and facility exit costs. The restructuring charge included termination benefits of $4,400, which consisted of $2,574 of cash severance and related benefits and $1,826 of accelerated stock-based compensation. The Company began
paying severance and related benefits in the third quarter of 2009 and will continue making payments into the third quarter of 2010.
As a
result of the Company vacating certain laboratory premises in the third quarter of 2009, the Company recorded a restructuring credit of $1,803 in the third quarter of 2009 associated with facility exit costs. The accrual for restructuring was
reduced by $1,000 of lease termination payments under the amendment to the lease, which were offset by the reduction of deferred rent and lease incentive obligations totaling $2,803. The Company made the final payment on the facilities component of
accrued restructuring on July 1, 2010.
The following table summarizes the activity of the accrued restructuring expense as of
June 30, 2010 related to the Companys 2009 strategic realignment:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at
December 31, 2009
|
|
Charges
|
|
Payments
|
|
|
Balance at
June 30, 2010
|
Termination benefits
|
|
$
|
274
|
|
$
|
|
|
$
|
(253
|
)
|
|
$
|
21
|
Facilities
|
|
|
1,000
|
|
|
|
|
|
(500
|
)
|
|
|
500
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
1,274
|
|
$
|
|
|
$
|
(753
|
)
|
|
$
|
521
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
11. Leases
On March 22, 2010, the Company exercised its option to extend its sublease for its Vancouver facility, through December 31, 2010. Under the
terms of this lease, the Company leases approximately 12,300 square feet. The monthly base rent is approximately $33.
12
12. Research and Development Agreements
Amgen Inc.
In December 2009, CombinatoRx
entered into a Research Collaboration Agreement (the Pilot Agreement) with Amgen Inc. (Amgen) focused on identifying synergistic combinations for two oncology targets of interest to Amgen. Under the Pilot Agreement,
CombinatoRx received a $750 payment in January 2010 to fund the initial research plan, and Amgen also agreed to reimburse CombinatoRx for laboratory supplies consumed. The initial research plan is through September 2010, and
Amgen may elect for CombinatoRx to do follow-up research at a per annum rate of $300 per full-time employee equivalent, plus the reimbursement of laboratory supplies. Amgen will also pay CombinatoRx a $1,000 milestone payment for each
Investigational New Drug filing by Amgen for a product candidate with new intellectual property generated by the collaboration. The Pilot Agreement also provides Amgen with a non-exclusive license to use the CombinatoRx Chalice
analyzer software in connection with the research collaboration. The Company recorded $323 and $682 of revenue under the Pilot Agreement in the three and six months ended June 30, 2010, respectively.
Mallinckrodt Inc., a subsidiary of Covidien plc
In June 2009, Neuromed entered into an asset purchase agreement with Mallinckrodt Inc., a subsidiary of Covidien plc (Covidien), to sell all
of the tangible and intangible assets associated with the product candidate Exalgo, including the rights to develop and commercialize the product candidate in the United States. As part of the agreement, Neuromed received upfront payments of
$15,000. The Company received a milestone payment of $40,000 following FDA approval of Exalgo in March 2010 and is eligible for tiered royalties on Covidiens net sales of Exalgo. The $40,000 milestone payment has been recorded in collaboration
and other revenue on the Statement of Operations for the six months ended June 30, 2010. Covidien will continue to pay these royalties on net sales for as long as it is selling Exalgo although the royalty rate will be reduced upon the earlier
to occur of generic competition or June 11, 2024.
Covidien launched the commercial sale of Exalgo during the second quarter of 2010. The
Company recognized $1,089 of revenue related to royalties from Covidiens sale of Exalgo during the three month period ended June 30, 2010. The royalties are included in collaboration and other revenue on the Statement of Operations.
Neuromed also entered into a development and transition services agreement with Covidien, pursuant to which the Company will perform certain
clinical development and regulatory activities relating to Exalgo. These activities are at Covidiens cost and expense, capped at $16,000. The Company recorded $306 and $511 during the three and six month periods ended June 30, 2010,
respectively. Through June 30, 2010, $8,030 has been billed to and received from Covidien related to the development and transition services agreement.
13. Income Taxes
As a result of the
acquisition of Neuromed, the Company has recorded a liability for unrecognized tax benefits of $2,685 and interest and penalties of $560 in other long-term liabilities. During the six months ended June 30, 2010, the Company reversed $910 of
unrecognized tax benefits and $306 of related accrued interest and penalties due to the expiration of the statute of limitations for certain tax years.
The following is a reconciliation of the Companys gross uncertain tax positions from December 31, 2009 to June 30, 2010 (in thousands):
|
|
|
|
|
December 31, 2009
|
|
$
|
2,685
|
|
Decrease related to positions taken in prior years
|
|
|
|
|
Increases related to positions taken by acquired subsidiary
|
|
|
|
|
Expiration of statute of limitations
|
|
|
(910
|
)
|
Foreign exchange revaluation
|
|
|
16
|
|
|
|
|
|
|
June 30, 2010
|
|
$
|
1,791
|
|
|
|
|
|
|
As of December 31, 2009, the Company had federal and state net operating loss carryforwards of approximately $142,060
and $111,584, respectively, available to reduce future taxable income and which expire at various dates beginning in 2009 through 2029. The Company also had federal and state research and development tax credit carryforwards of approximately$7,398
and $5,943, respectively, available to reduce future tax liabilities and which expire at various dates beginning in 2015 through 2029.
Utilization of the net operating loss and research and development credit carryforwards may be subject to a substantial annual limitation under Internal
Revenue Code Section 382 of the Internal Revenue Code of 1986 due to ownership change limitations that have occurred previously or that could occur in the future. In 2010, an analysis was conducted in accordance with the provisions of
Section 382 of the Internal Revenue Code in order to determine whether the amount of net operating losses and research and
13
development tax credits are subject to annual limitations for federal and state income tax purposes. Based on this analysis, the Company concluded that the federal and state net operating losses
available to reduce future taxable income are $24,486 and $0, respectively. The Company also has state research credits of $5,943 available to reduce future tax liabilities. The remaining federal and state net operating losses and research and
development tax credits will not be utilized due to limitations under Internal Revenue Code Section 382.
The Company recorded an income
tax benefit of $300 in the three month period ended June 30, 2010. The income tax benefit was the result of an adjustment to the Neuromed tax provision for a period prior to the merger date. The Company does not believe that the previously
unrecorded amount is material to the results of operations or the financial position of the Company as of and for the year ended December 31, 2009 or as of and for the year ending December 31, 2010. As such, since the measurement period
associated with the acquisition accounting for Neuromed has ended, the adjustment was recorded as an income tax benefit in the three month period ended June 30, 2010 in accordance with ASC 805
Business Combinations
.
14
Item 2.
|
Managements Discussion and Analysis of Financial Condition and Results of Operations
|
You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our
financial statements and their notes appearing elsewhere in this quarterly report. The following discussion contains forward-looking statements that involve risks and uncertainties. Our actual results and the timing of certain events could differ
materially from those anticipated in these forward-looking statements as a result of certain factors, including those discussed below and elsewhere in this quarterly report or in our annual report on form 10-K.
Overview
CombinatoRx
develops novel drug candidates with a focus on the treatment of pain and inflammation. We have entered into multiple revenue-generating collaborations with large pharmaceutical companies and have a portfolio of clinical-stage product candidates
targeting pain, inflammation and other neurodegenerative diseases. We also utilize our selective ion-channel modulation platform and combination drug discovery technology to discover new product candidates for our portfolio.
On December 21, 2009, we completed our merger with Neuromed Pharmaceuticals Inc., or Neuromed. Upon the
consummation of the merger, former Neuromed stockholders were issued an aggregate of 14,937,654 shares of our common stock and 67,826,875 shares of our common stock were issued into escrow. When the FDA did not approve
Exalgo
TM
prior to January 1, 2010, 29,943,752 shares
of our common stock held in escrow were cancelled. On March 1, 2010, the FDA approved Exalgo for the management of moderate to severe pain in opioid tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended
period of time, resulting in the release to former Neuromed stockholders of the remaining 37,883,123 shares of our common stock held in escrow.
The United States commercial rights to Exalgo were acquired by Covidien from Neuromed in June 2009. Under the agreement, Covidien is
responsible for all commercialization activities for Exalgo in the United States, including marketing and sales, and for all post-approval regulatory activities. We received a $40.0 million milestone payment following FDA approval of Exalgo, and are
eligible to receive tiered royalties on net sales of Exalgo by Covidien following its commercial launch. The Company has recognized $1.1 million in revenue related to these royalties through June 30, 2010.
Following the sale of all rights to Exalgo to Covidien, our most advanced product candidate is
Synavive
TM
, a product candidate we have been developing to
treat immuno-inflammatory disorders. During 2008 we studied Synavive in a multi-center Phase 2 clinical trial of 279 subjects with knee osteoarthritis, the COMET-1 study. The COMET-1 study was completed in September 2008, and the results of the
study were disclosed in October 2008. Subjects who completed the 14-week duration of the COMET-1 study were eligible to participate in an extension study designed to investigate the long-term safety and durability of response for Synavive. The
COMET-1 extension study of Synavive was completed in June 2009. We are currently finalizing our plans for further Phase 2 clinical trials of Synavive. Following the merger with Neuromed in December 2009, we have also been performing research and
development on our proprietary ion channel modulators which have been advanced through preclinical research and development. We have also been using our combination high throughput screening technology platform, or cHTS, which includes both
customized hardware and software elements, to perform our obligations with our collaboration partners. In addition to Synavive, during 2009, CombinatoRx had been advancing three other product candidates through clinical research and development:
CRx-401 for Type 2 diabetes, CRx-191 for psoriasis and CRx-197 for psoriasis through clinical research and development.
As of
June 30, 2010, we had an accumulated deficit of $231.3 million. We had net losses from continuing operations of $11.7 million and $15.6 million for the six months ended June 30, 2010 and 2009, respectively.
Our management currently uses consolidated financial information in determining how to allocate resources and assess performance. We have
determined that we conduct operations in one business segment. For the three months ended June 30, 2010, $1.2 million and $1.7 million of our revenues were generated in Canada and the United States, respectively. For the six months ended
June 30, 2010, $41.5 million and $2.8 million of our revenues were generated in Canada and the United States, respectively. As of June 30, 2010, $6.4 million and $1.1 million of our long-lived assets were located in the United States and
Canada, respectively.
Critical Accounting Policies
We believe that several accounting policies are important to understanding our historical and future performance. We refer to these
policies as critical because these specific areas generally require us to make judgments and estimates about matters that are uncertain at the time we make the estimate, and different estimateswhich also would have been
reasonablecould have been used, which would have resulted in different financial results.
The critical accounting
policies we identified in our most recent Annual Report on Form 10-K for the fiscal year ended December 31, 2009 related to business combinations, intangible assets, revenue recognition, stock-based compensation, accrued expenses and
income taxes. There have not been any significant changes to our critical accounting policies in 2010. It is important that
15
the discussion of our operating results that follows be read in conjunction with the critical accounting policies disclosed in our Annual Report on Form 10-K, as filed with the SEC on
March 26, 2010.
Results of Operations
Comparison of the Three Months ended June 30, 2010 and June 30, 2009
Revenue.
For the three months ended June 30, 2010, we recorded $2.9 million of revenue from our research and development
collaborations with Mallinckrodt, Inc., a subsidiary of Covidien plc, or Covidien, Novartis Institutes of BioMedical Research, Inc., or Novartis, Amgen, Inc., or Amgen, Fovea Pharmaceuticals, or Fovea, and from grants from the National Institutes of
Allergy and Infectious Diseases, or NIAID, the United States Army Medical Research Institute for Infectious Diseases, or USAMRIID. Covidien launched the commercial sale of Exalgo in the second quarter of 2010, and we began to earn royalty payments
from Covidien in the second quarter of 2010 based upon a percentage of Covidiens net sales of Exalgo. During the three months ended June 30, 2010, we recognized approximately $1.1 million in revenue related to royalties from Covidien
based on sales of Exalgo. Our royalty revenue from Covidien relating to the net sales of Exalgo could fluctuate significantly in future periods due to a number of factors outside our control, and it may cause our operating results for a particular
quarterly or annual period to vary in a material manner. As a result, royalty revenue from Exalgo sales during specific quarterly periods may not be predictive of future royalty revenue for CombinatoRx from net sales of Exalgo.
For the three months ended June 30, 2009, we recorded $3.3 million of revenue from our research and development collaborations
with Novartis, Fovea, Angiotech Pharmaceuticals, Inc., or Angiotech, Cystic Fibrosis Foundation Therapeutics, or CFFT, Charleys Fund, the Nash Avery Foundation and GMT Charitable Research, LLC, or the DMD Foundations, and from grants from the
NIAID and USAMRIID.
Research and Development.
Research and development expense for the three months ended
June 30, 2010 was $4.6 million compared to $6.1 million for the three months ended June 30, 2009. The $1.5 million decrease was primarily due to a $0.4 million increase in consulting and preclinical expenses offset by a decrease of
$0.6 million in formulations and external clinical expenses and a $1.3 million decrease in laboratory supplies, facilities, depreciation and other overhead costs associated with the 2008 and 2009 restructurings.
The table below summarizes our allocation of research and development expenses to Exalgo, our clinical programs, including Synavive, and
our preclinical programs for the three months ended June 30, 2010 and 2009. Our internal project costing methodology does not allocate all of the personnel and other indirect costs from all of our research and development departments to
specific clinical and preclinical programs, and such unallocated costs are further summarized in the table below. Unallocated clinical program costs consist primarily of the personnel and other expenses for our clinical operations, medical affairs
and clinical program management departments, all of which supported the development of Exalgo and our clinical product candidate, Synavive. Preclinical program costs consist of the personnel and other expenses allocated to our internally funded
preclinical programs, other than our ion channel program, as well as the direct costs allocated to all of our research collaborations. Unallocated clinical and preclinical program costs consist primarily of the personnel and other expenses for our
formulations, pharmacology, regulatory, quality, and discovery departments, all of which supported the development of our clinical product candidates, including Exalgo and Synavive, as well as our preclinical product candidates, including our ion
channel program. Infrastructure and support costs consist of facility costs, depreciation and amortization and costs for research and development support personnel such as our informatics and facilities departments.
|
|
|
|
|
|
|
|
|
Three Months Ended
June 30,
(in thousands)
|
|
2010
|
|
2009
|
Exalgo
|
|
$
|
148
|
|
$
|
|
Synavive
|
|
|
131
|
|
|
793
|
Unallocated clinical program costs
|
|
|
356
|
|
|
385
|
|
|
|
|
|
|
|
Total clinical program costs
|
|
|
635
|
|
|
1,178
|
Preclinical program costs
|
|
|
932
|
|
|
1,520
|
Ion channel program costs
|
|
|
1,182
|
|
|
|
Unallocated clinical and preclinical program costs
|
|
|
515
|
|
|
495
|
Infrastructure and support costs
|
|
|
1,181
|
|
|
2,576
|
Non-cash employee and non-employee stock-based compensation expense
|
|
|
172
|
|
|
337
|
|
|
|
|
|
|
|
Total research and development expenses
|
|
$
|
4,617
|
|
$
|
6,106
|
|
|
|
|
|
|
|
16
Following the FDA approval of Exalgo, we expect our research and development costs to remain
constant until we initiate additional clinical trials, as we now focus on drug discovery, research, preclinical development and advancing select product candidates through clinical development. We may select product candidates and research projects
for further development on an ongoing basis in response to their preclinical and clinical success and commercial potential. Due to the fact that our most advanced product candidates are in the early stages of development, we cannot estimate
anticipated completion dates and when we might receive material net cash inflows from future collaboration agreements with sponsored research funding, up-front payments, milestones or royalties.
General and Administrative.
General and administrative expense for the three months ended June 30, 2010 was $2.6 million
compared to $4.8 million for the three months ended June 30, 2009. The $2.2 million decrease was primarily due to a decrease of $1.4 million in legal and consulting fees, a decrease of $0.2 million in salaries and benefit expenses due to
decreased headcount, a decrease of $0.6 million in stock-based compensation expense, and a $0.3 million reversal of accrued interest and penalties due to the expiration of the statute of limitations for certain tax years.
Amortization of Intangible Asset.
For the three months ended June 30, 2010, we recorded $4.7 million of amortization expense
related to the Exalgo intangible asset acquired in the merger with Neuromed on December 21, 2009. The intangible asset is being amortized in a manner which reflects our estimate of the future undiscounted cash flows we expect to receive over
the five-year patent life of Exalgo.
Interest Income.
Interest income for each of the three months ended June 30,
2010 and 2009 was less than $0.1 million. Interest income remained consistent despite the $23.1 million increase in cash and cash equivalents and short-term investments from June 30, 2009 to June 30, 2010, due to significantly lower
interest rates.
Benefit for Income Taxes.
For the three months ended June 30, 2010, we recognized a tax benefit
of $0.3 million. The income tax benefit was the result of an adjustment to the Neuromed tax provision for a period prior to the merger date. The Company does not believe that the previously unrecorded amount is material to the results of operations
or the financial position of the Company as of and for the year ended December 31, 2009 or as of and for the year ending December 31, 2010. As such, since the measurement period associated with the acquisition accounting for Neuromed has
ended, the adjustment was recorded as an income tax benefit in the three month period ended June 30, 2010 in accordance with ASC 805
Business Combinations
.
Gain from Discontinued Operations.
On June 2, 2009, we divested our 51% equity ownership interest in CombinatoRx Singapore,
by selling our 2,602,041 ordinary shares of CombinatoRx Singapore to the other shareholder of CombinatoRx Singapore, BioMedical Sciences, for nominal consideration. We also entered into a share purchase agreement with CombinatoRx Singapore and
BioMedical Sciences and an intellectual property assignment agreement and transition services agreement with CombinatoRx Singapore. Under the intellectual property assignment agreement, CombinatoRx Singapore has been assigned and retains all
infectious disease intellectual property developed by CombinatoRx Singapore with our assistance since the formation of CombinatoRx Singapore. Under the share purchase agreement, we agreed not to compete with CombinatoRx Singapore in the discovery
and development of product candidates to treat certain infectious diseases in substantially all markets until June 2, 2010. We recorded a gain from discontinued operations of $15.1 million during the three months ended June 30, 2009.
Comparison of the Six Months ended June 30, 2010 and June 30, 2009
Revenue.
For the six months ended June 30, 2010, we recorded $44.3 million of revenue from our research and development
collaborations with Covidien, Novartis, Amgen, Fovea, NIAID and USAMRIID. We received a $40.0 million milestone payment from Covidien, following the FDA approval of Exalgo on March 1, 2010. Covidien launched the commercial sale of Exalgo in the
second quarter of 2010, and we began to receive royalty payments from Covidien in the second quarter of 2010 based upon a percentage of Covidiens net sales of Exalgo. During the six months ended June 30, 2010, we recognized $1.1 million
in revenue related to royalties from Covidien based on sales of Exalgo. For the six months ended June 30, 2009, we recorded $6.0 million of revenue from our research and development collaborations with Angiotech, CFFT, CHDI, Inc., the DMD
Foundations and from grants from the NIAID and USAMRIID. The increase in revenue is primarily due to the $40.0 million milestone payment received from Covidien upon the FDA approval of Exalgo.
Research and Development.
Research and development expense for the six months ended June 30, 2010 was $12.0 million compared
to $13.2 million for the six months ended June 30, 2009. The $1.2 million decrease was primarily due to an increase of $1.8 million in salary and benefit expenses related to the addition of Neuromed personnel, a $1.2 million increase in
consulting and preclinical expenses and a $0.4 million increase in stock-based compensation expense related to the approval of Exalgo satisfying certain performance based vesting criteria for stock-based awards offset by a decrease of $2.9 million
in formulations and external clinical expenses and a $1.7 million decrease in laboratory supplies, facilities, depreciation and other overhead costs associated with the 2008 and 2009 restructurings.
The table below summarizes our allocation of research and development expenses to Exalgo, our clinical programs, including Synavive, and
our preclinical programs for the six months ended June 30, 2010 and 2009. Our internal project costing methodology does not allocate all of the personnel and other indirect costs from all of our research and development departments to specific
clinical
17
and preclinical programs, and such unallocated costs are further summarized in the table below. Unallocated clinical program costs consist primarily of the personnel and other expenses for our
clinical operations, medical affairs and clinical program management departments, all of which supported the development of Exalgo and our clinical product candidate, Synavive. Preclinical program costs consist of the personnel and other expenses
allocated to our internally funded preclinical programs, other than our ion channel program, as well as the direct costs allocated to all of our research collaborations. Unallocated clinical and preclinical program costs consist primarily of the
personnel and other expenses for our formulations, pharmacology, regulatory, quality, and discovery departments, all of which supported the development of our clinical product candidates, including Exalgo and Synavive, as well as our preclinical
product candidates, including our ion channel program. Infrastructure and support costs consist of facility costs, depreciation and amortization and costs for research and development support personnel such as our informatics and facilities
departments.
|
|
|
|
|
|
|
|
|
Six Months Ended
June 30,
(in thousands)
|
|
2010
|
|
2009
|
Exalgo
|
|
$
|
494
|
|
$
|
|
Synavive
|
|
|
166
|
|
|
2,487
|
Unallocated clinical program costs
|
|
|
746
|
|
|
1,458
|
|
|
|
|
|
|
|
Total clinical program costs
|
|
|
1,406
|
|
|
3,945
|
Preclinical program costs
|
|
|
2,167
|
|
|
3,125
|
Ion channel program costs
|
|
|
2,505
|
|
|
|
Unallocated clinical and preclinical program costs
|
|
|
1,095
|
|
|
1,051
|
Infrastructure and support costs
|
|
|
3,598
|
|
|
4,271
|
Non-cash employee and non-employee stock-based compensation expense
|
|
|
1,227
|
|
|
851
|
|
|
|
|
|
|
|
Total research and development expenses
|
|
$
|
11,998
|
|
$
|
13,243
|
|
|
|
|
|
|
|
Following the FDA approval of Exalgo, we expect our
research and development costs to remain constant until we initiate additional clinical trials, as we now focus on drug discovery, research, preclinical development and advancing select product candidates through clinical development. We may select
product candidates and research projects for further development on an ongoing basis in response to their preclinical and clinical success and commercial potential. Due to the fact that our most advanced product candidates are in the early stages of
development, we cannot estimate anticipated completion dates and when we might receive material net cash inflows from future collaboration agreements with sponsored research funding, up-front payments, milestones or royalties.
General and Administrative.
General and administrative expense for the six months ended June 30, 2010 was $6.4 million
compared to $8.5 million for the six months ended June 30, 2009. The $2.1 million decrease was primarily due to a decrease of $1.1 million in legal and consulting fees, a decrease of $0.1 million in salaries and benefit expenses and a
decrease of $0.8 million in stock-based compensation expense.
Amortization of Intangible Asset.
For the six months
ended June 30, 2010, we recorded $9.4 million of amortization expense related to the Exalgo intangible asset acquired in the merger with Neuromed on December 21, 2009. The intangible asset is being amortized in a manner which reflects our
estimate of the future undiscounted cash flows we expect to receive over the five-year patent life of Exalgo.
Interest
Income.
Interest income for the six months ended June 30, 2010 was less than $0.1 million compared to $0.2 million for the six months ended June 30, 2009. The decrease was primarily due to significantly lower average interest rates for
the securities held in our investment portfolio.
Loss on Revaluation of Contingent Consideration.
For the six months
ended June 30, 2010, we recognized a loss in the amount of $29.3 million on the revaluation of contingent consideration in connection with the Neuromed merger. This loss represents the change in fair value of the contingent consideration at
December 31, 2009 and March 1, 2010 when the contingent consideration was settled. On March 1, 2010, 37,883,123 escrow shares were released to former Neuromed stockholders as settlement of the contingent consideration. The change in
value is due to the fair value of shares released from escrow being greater than our probability weighted estimate as of December 31, 2009.
Benefit for Income Taxes.
For the six months ended June 30, 2010, we recognized a tax benefit of $1.2 million primarily
related to the reversal of an unrecognized tax benefit for an uncertain tax position due to the expiration of the relevant statute of limitations.
Gain from Discontinued Operations.
On June 2, 2009, we divested our 51% equity ownership interest in CombinatoRx Singapore,
by selling our 2,602,041 ordinary shares of CombinatoRx Singapore to the other shareholder of CombinatoRx Singapore,
18
BioMedical Sciences, for nominal consideration. We also entered into a share purchase agreement with CombinatoRx Singapore and BioMedical Sciences and an intellectual property assignment
agreement and transition services agreement with CombinatoRx Singapore. Under the intellectual property assignment agreement, CombinatoRx Singapore has been assigned and retains all infectious disease intellectual property developed by CombinatoRx
Singapore with our assistance since the formation of CombinatoRx Singapore. Under the share purchase agreement, we agreed not to compete with CombinatoRx Singapore in the discovery and development of product candidates to treat certain infectious
diseases in substantially all markets until June 2, 2010. We recorded a gain from discontinued operations of $14.1 million during the six months ended June 30, 2009.
Liquidity and Capital Resources
As of June 30, 2010, we had cash, cash equivalents and short-term investments of approximately $52.2 million, which includes $2.6
million of restricted cash. Our funds are primarily invested in short-term, government agency securities, United States Treasury money market funds and short-term corporate debt securities, and as such, we do not believe there is significant risk in
our investment portfolio as of June 30, 2010.
During the six months ended June 30, 2010, we received $41.7 million
from Covidien, which included a $40.0 million milestone payment related to the March 1, 2010 FDA approval of Exalgo. In addition, we received $3.3 million in payments from our collaborations and research and development agreements with
Novartis, Amgen, Fovea and Covidien and grants from the NIAID and USAMRIID. We expect that our sources of funding in the future will also include, subject to our satisfying conditions, additional research funding, license fees, potential milestone
payments and royalties relating to our collaboration and research and development agreements with Covidien, Novartis, Fovea and Amgen and government grants from the NIAID and USAMRIID and any other collaborative agreements into which we might enter.
Based on our current operating plans, we expect our resources to be sufficient to fund our planned operations into 2014.
However, we may require significant additional funds earlier than we currently expect if our research and development expenses exceed our current expectations or our collaboration funding is less than our current expectations. We may seek additional
funding through collaboration agreements and public or private financings of debt or equity capital. On April 16, 2010, we filed a shelf registration statement on Form S-3 under the Securities Act of 1933, as amended (SEC File
No. 333-166116), with the SEC covering the registration of senior debt securities, subordinated debt securities, preferred stock, common stock, warrants, units or any combination of the foregoing securities (the Securities), in an
aggregate amount of $50.0 million, which was declared effective by the SEC on April 29, 2010. These Securities may be offered from time to time in amounts, at prices and on terms to be determined at the time of sale. We believe the shelf
registration provides additional financing flexibility to meet potential future funding requirements and the ability to take advantage of potentially attractive capital market conditions. However, funding may not be available to us on acceptable
terms or at all. If we are unable to obtain funding on a timely basis, we may be required to significantly curtail one or more of our research or development programs or our operations. We also could be required to seek funds through arrangements
with collaborators or others that may require us to relinquish rights to some of our technologies or product candidates which we would otherwise pursue on our own.
Our operating activities from continuing operations provided cash of $26.7 million for the six months ended June 30, 2010 and used
cash of $13.2 million for the six months ended June 30, 2009. The increase in the net cash provided by operating activities was primarily attributed to our receipt of a $40.0 million milestone payment from Covidien related to the FDA approval
of Exalgo, offset by working capital adjustments in accounts payable, accrued expenses and accrued restructuring.
Our
investing activities from continuing operations used cash of $33.3 million for the six months ended June 30, 2010 and provided cash of $9.2 million for the six months ended June 30, 2009. The cash used in investing activities for the
six months ended June 30, 2010 was primarily due to purchases of short-term investments while the cash provided by investing activities was primarily due to sales and maturities of short-term investments in the six months ended June 30,
2009.
Our financing activities from continuing operations used cash of less than $0.1 million for the six months ended
June 30, 2010 and were not a significant source of cash for the six months ended June 30, 2009.
Off-Balance Sheet Arrangements
We do not have any off-balance sheet arrangements or any relationships with unconsolidated entities of financial
partnerships, such as entities often referred to as structured finance or special purpose entities.
New Accounting Standards
Refer to Note 2,
Recent Accounting Pronouncements,
in Notes to Condensed Consolidated Financial
Statements, for a discussion of new accounting standards.
19
Item 3.
|
Quantitative and Qualitative Disclosure about Market Risk
|
Not applicable.
Item 4.
|
Controls and Procedures
|
Evaluation of
Disclosure Controls and Procedures
As required by Rule 13a15(b) of the Securities Exchange Act of 1934, as
amended (the 1934 Act), the Companys management, including the Chief Executive Officer and the Chief Financial Officer, the Companys principal executive officer and principal financial officer, respectively, conducted an
evaluation as of the end of the period covered by this Quarterly Report on Form 10-Q of the effectiveness of the design and operation of the Companys disclosure controls and procedures. Based on that evaluation, the Companys Chief
Executive Officer and Chief Financial Officer concluded that the Companys disclosure controls and procedures are effective at the reasonable assurance level in ensuring that information required to be disclosed by the Company in the reports
that it files or submits under the 1934 Act is recorded, processed, summarized and reported within the time periods specified in the SECs rules and forms.
Changes in Internal Control
As required by Rule 13a-15(d) of the 1934 Act, the Companys management, including the Chief Executive Officer and the
Chief Financial Officer, conducted an evaluation of the internal control over financial reporting to determine whether any changes
occurred
during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, the Companys internal control over financial reporting. Based on that evaluation, the Chief
Executive Officer and Chief Financial Officer concluded no such changes during the fiscal quarter covered by this Quarterly Report on Form 10-Q materially affected, or were reasonably likely to materially affect, the Companys internal
control over financial reporting.
20
PART II
RISK FACTORS THAT
MAY AFFECT FUTURE RESULTS
Information regarding risk factors appears in Item 1A of our Annual Report on
Form 10-K for the year ended December 31, 2009, which was filed with the SEC on March 26, 2010, as updated from time to time in our subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings
with the SEC. There have been no material changes in our risk factors except as disclosed below.
Our royalty revenue from
Covidien relating to the net sales of Exalgo could vary significantly in future periods and royalty revenue from Exalgo sales during quarterly periods may not be predictive of future royalty revenue for CombinatoRx from sales of Exalgo.
Our revenue from net sales of Exalgo by Covidien may fluctuate from period to period due to:
|
|
|
the rate of market acceptance of Exalgo as a new therapy by physicians and payors;
|
|
|
|
fluctuations in future sales of Exalgo due to competition from other products;
|
|
|
|
reimbursement and pricing for Exalgo under commercial or government plans;
|
|
|
|
permitted deductions from gross sales of Exalgo relating to estimates of sales returns, credits and allowances, normal trade and cash discounts,
managed care sales rebates and other allocated costs;
|
|
|
|
inventory levels of Exalgo with wholesalers not matching actual demand for Exalgo;
|
|
|
|
the duration of market exclusivity of Exalgo;
|
|
|
|
the timing of approvals, if any, for other competitive products or the future availability of generic versions of branded long-acting opioids;
|
|
|
|
manufacturing difficulties; or
|
|
|
|
other factors that affect the sales of a pharmaceutical product.
|
All of these factors are outside our control, and any of these events may cause our revenues to fluctuate significantly from quarter to
quarter, and in some cases may cause our operating results for a particular quarterly or annual period to vary in a material manner.
The Exhibits
listed in the Exhibit Index immediately preceding the Exhibits are filed as a part of this Quarterly Report on Form 10-Q.
21
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned thereunto duly authorized.
|
|
|
COMBINATORX, INCORPORATED
|
|
|
By:
|
|
/
S
/ J
USTIN
A.
R
ENZ
|
|
|
Justin A. Renz
|
|
|
Senior Vice President and Chief Financial Officer
(Authorized Officer and Principal Financial Officer)
|
Date: August 10, 2010
22
EXHIBIT INDEX
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Incorporated by Reference to:
|
Exhibit
No.
|
|
Description
|
|
Form or
Schedule
|
|
Exhibit
No.
|
|
Filing
Date
with
SEC
|
|
SEC File
Number
|
|
|
|
|
|
|
2.1
|
|
Agreement and Plan of Merger, dated as of June 30, 2009, by and among CombinatoRx, Incorporated, PawSox, Inc., Neuromed Pharmaceuticals Inc., Neuromed Pharmaceuticals Ltd. and
the Stockholder Representative named therein
|
|
8-K
|
|
2.1
|
|
07/01/2009
|
|
000-51171
|
|
|
|
|
|
|
2.2
|
|
Escrow Agreement, dated as of June 30, 2009, by and among CombinatoRx, Incorporated, Computershare Trust Company, N.A. and the Stockholder Representative
|
|
8-K
|
|
2.2
|
|
07/01/2009
|
|
000-51171
|
|
|
|
|
|
|
3.1
|
|
Sixth Amended and Restated Certificate of Incorporation of CombinatoRx, Incorporated
|
|
S-1/A
|
|
3.2
|
|
11/04/2005
|
|
333-121173
|
|
|
|
|
|
|
3.2
|
|
Certificate of Amendment to the CombinatoRx Sixth Amended and Restated Certificate of Incorporation
|
|
8-K
|
|
3.1
|
|
12/21/2009
|
|
000-51171
|
|
|
|
|
|
|
3.3
|
|
Amended and Restated By-Laws of CombinatoRx, Incorporated
|
|
8-K
|
|
3.1
|
|
06/04/2007
|
|
000-51171
|
|
|
|
|
|
|
4.1
|
|
Specimen CombinatoRx, Incorporated Common Stock Certificate
|
|
S-1/A
|
|
4.1
|
|
01/19/2005
|
|
333-121173
|
|
|
|
|
|
|
4.2
|
|
Warrant issued to General Electric Capital Corporation on September 15, 2004, to purchase up to 8,892 shares of CombinatoRx, Incorporateds Common Stock
|
|
S-1
|
|
10.7
|
|
12/10/2004
|
|
333-121173
|
|
|
|
|
|
|
4.3
|
|
Warrant issued to General Electric Capital Corporation on June 28, 2005, to purchase 471 shares of CombinatoRx, Incorporateds Common Stock
|
|
10-K
|
|
4.5
|
|
03/20/2006
|
|
000-51171
|
|
|
|
|
|
|
4.4
|
|
Warrant issued to Silicon Valley Bank on April 25, 2001, to purchase up to 10,019 shares of CombinatoRx, Incorporateds Common Stock
|
|
S-1
|
|
10.9
|
|
12/10/2004
|
|
333-121173
|
|
|
|
|
|
|
4.5
|
|
Registration Rights Agreement dated as of April 25, 2001, by and between Silicon Valley Bank and CombinatoRx, Incorporated
|
|
S-1
|
|
10.10
|
|
12/10/2004
|
|
333-121173
|
|
|
|
|
|
|
4.6
|
|
Form of Warrant to purchase shares of CombinatoRx, Incorporateds Stock, together with a schedule of warrant holders
|
|
S-1
|
|
10.11
|
|
12/10/2004
|
|
333-121173
|
|
|
|
|
|
|
4.7
|
|
Form of Warrant issued to BioMedical Sciences Investment Fund Pte Ltd. on August 19, 2005 to purchase up to 25,000 shares of CombinatoRx, Incorporateds Common Stock
|
|
S-1
|
|
10.45
|
|
08/19/2005
|
|
333-121173
|
|
|
|
|
|
|
4.8
|
|
Registration Rights Agreement, dated as of June 30, 2009, among CombinatoRx, Incorporated and the investors set forth therein
|
|
S-4
|
|
4.11
|
|
08/07/2009
|
|
333-161146
|
|
|
|
|
|
|
#10.1
|
|
2000 Stock Option Plan, as amended
|
|
S-1
|
|
10.1
|
|
12/10/2004
|
|
333-121173
|
|
|
|
|
|
|
#10.2
|
|
Amended and Restated 2004 Incentive Plan
|
|
S-8
|
|
4.1
|
|
04/16/2010
|
|
333-166118
|
|
|
|
|
|
|
#10.3
|
|
Form Incentive Stock Option Agreement under the 2004 Incentive Plan
|
|
10-K
|
|
10.3
|
|
03/20/2006
|
|
000-51171
|
|
|
|
|
|
|
#10.4
|
|
Form Non-Qualified Option Agreement under the 2004 Incentive Plan
|
|
10-K
|
|
10.4
|
|
03/20/2006
|
|
000-51171
|
|
|
|
|
|
|
#10.5
|
|
Nonqualified Deferred Compensation Plan, effective December 1, 2007
|
|
S-8
|
|
4.1
|
|
11/30/2007
|
|
333-147745
|
|
|
|
|
|
|
#10.6
|
|
Employment Letter Agreement with Jason F. Cole, dated as of January 23, 2006.
|
|
10-K
|
|
10.15
|
|
03/20/2006
|
|
000-51171
|
23
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Incorporated by Reference to:
|
Exhibit
No.
|
|
Description
|
|
Form or
Schedule
|
|
Exhibit
No.
|
|
Filing
Date
with
SEC
|
|
SEC File
Number
|
|
|
|
|
|
|
#10.7
|
|
Amendment to Employment Agreement with Jason Cole, dated December 15, 2008.
|
|
10-K
|
|
10.13
|
|
03/16/2009
|
|
000-51171
|
|
|
|
|
|
|
#10.8
|
|
Letter Agreement Re: Retention Bonus with Jason Cole, dated December 16, 2008.
|
|
10-K
|
|
10.13
|
|
03/16/2009
|
|
000-51171
|
|
|
|
|
|
|
#10.9
|
|
Amended and Restated Restricted Stock Award Agreement, dated September 5, 2008, by and between Jason Cole and CombinatoRx, Incorporated.
|
|
10-Q
|
|
10.25
|
|
11/10/2008
|
|
000-51171
|
|
|
|
|
|
|
#10.10
|
|
Employment Letter Agreement with Justin Renz, dated as of August 31, 2006.
|
|
S-4
|
|
10.14
|
|
08/07/2009
|
|
333-161146
|
|
|
|
|
|
|
#10.11
|
|
Letter Agreement Re: Retention Bonus with Justin Renz, dated December 12, 2008.
|
|
S-4
|
|
10.15
|
|
08/07/2009
|
|
333-161146
|
|
|
|
|
|
|
#10.12
|
|
Letter Agreement Re: Severance Arrangements with Justin Renz, dated December 12, 2008.
|
|
S-4
|
|
10.16
|
|
08/07/2009
|
|
333-161146
|
|
|
|
|
|
|
#10.13
|
|
Separation Agreement, dated as of January 14, 2010 between CombinatoRx, Incorporated and Robert Forrester.
|
|
10-Q
|
|
10.13
|
|
05/12/2010
|
|
000-51171
|
|
|
|
|
|
|
#10.14
|
|
Employment Agreement with Mark H. N. Corrigan, dated as of March 8, 2010.
|
|
8-K
|
|
10.1
|
|
03/08/2010
|
|
000-51171
|
|
|
|
|
|
|
#10.15
|
|
Form Incentive Stock Option Agreement with Mark H. N. Corrigan, dated as of January 15, 2010.
|
|
8-K
|
|
10.1
|
|
01/20/2010
|
|
000-51171
|
|
|
|
|
|
|
#10.16
|
|
Form Nonstatutory Stock Option Agreement with Mark H. N. Corrigan, dated as of January 15, 2010.
|
|
8-K
|
|
10.2
|
|
01/20/2010
|
|
000-51171
|
|
|
|
|
|
|
#10.17
|
|
Form Restricted Stock Unit Agreement between CombinatoRx and Mark Corrigan, dated as of January 15, 2010.
|
|
8-K
|
|
10.3
|
|
01/20/2010
|
|
000-51171
|
|
|
|
|
|
|
#10.18
|
|
Award Letter from Neuromed Pharmaceuticals to Christopher C. Gallen, accepted and agreed to as of June 19, 2009.
|
|
S-4
|
|
10.43
|
|
08/07/2009
|
|
333-161146
|
|
|
|
|
|
|
#10.19
|
|
Revised Offer Letter from Neuromed Pharmaceuticals accepted by Christopher C. Gallen, dated May 27, 2004.
|
|
S-4
|
|
10.45
|
|
08/07/2009
|
|
333-161146
|
|
|
|
|
|
|
#10.20
|
|
Confidentiality and Assignment of Proprietary Developments Agreement between Neuromed Technologies Inc. and Christopher C. Gallen, dated April 2005.
|
|
S-4
|
|
10.46
|
|
08/07/2009
|
|
333-161146
|
|
|
|
|
|
|
#10.21
|
|
Neuromed Pharmaceuticals Inc. Special Equity Incentive Plan.
|
|
S-4/A
|
|
10.51
|
|
09/16/2009
|
|
333-161146
|
|
|
|
|
|
|
#10.22
|
|
CombinatoRx Form of Restricted Stock Unit Agreement for awards granted under the Neuromed Pharmaceuticals Inc. Special Equity Incentive Plan (Directors).
|
|
S-4/A
|
|
10.52
|
|
09/16/2009
|
|
333-161146
|
|
|
|
|
|
|
#10.23
|
|
CombinatoRx Form of Restricted Stock Unit Agreement for awards granted under the Neuromed Pharmaceuticals Inc. Special Equity Incentive Plan (Executives).
|
|
S-4/A
|
|
10.53
|
|
09/16/2009
|
|
333-161146
|
|
|
|
|
|
|
10.24
|
|
Form of Indemnification Agreement for Directors.
|
|
8-K
|
|
10.1
|
|
12/21/2009
|
|
000-51171
|
|
|
|
|
|
|
10.25
|
|
Research Project Cooperative Agreement, dated April 10, 2005, between the National Institutes of Health and CombinatoRx, Incorporated.
|
|
S-1/A
|
|
10.37
|
|
08/19/2005
|
|
333-121173
|
24
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Incorporated by Reference to:
|
Exhibit
No.
|
|
Description
|
|
Form or
Schedule
|
|
Exhibit
No.
|
|
Filing
Date
with
SEC
|
|
SEC File
Number
|
|
|
|
|
|
|
10.26
|
|
Termination Agreement, dated as of June 2, 2009, by and among CombinatoRx (Singapore) Pte Ltd, Biomedical Sciences Investment Fund Pte Ltd and CombinatoRx, Incorporated.
|
|
8-K
|
|
10.1
|
|
06/02/2009
|
|
000-51171
|
|
|
|
|
|
|
10.27
|
|
Share Purchase Agreement, dated as of June 2, 2009, by and among CombinatoRx (Singapore) Pte Ltd, Biomedical Sciences Investment Fund Pte Ltd and CombinatoRx,
Incorporated.
|
|
8-K
|
|
10.2
|
|
06/02/2009
|
|
000-51171
|
|
|
|
|
|
|
10.28
|
|
Intellectual Property Assignment Agreement, dated as of June 2, 2009, by and between CombinatoRx (Singapore) Pte Ltd and CombinatoRx, Incorporated.
|
|
8-K
|
|
10.3
|
|
06/02/2009
|
|
000-51171
|
|
|
|
|
|
|
10.29
|
|
Transition Services Agreement, dated as of June 2, 2009, by and between CombinatoRx (Singapore) Pte Ltd and CombinatoRx, Incorporated.
|
|
8-K
|
|
10.4
|
|
06/02/2009
|
|
000-51171
|
|
|
|
|
|
|
10.30
|
|
Research and License Agreement, dated as of October 3, 2005, between Angiotech Pharmaceuticals, Inc. and CombinatoRx, Incorporated.
|
|
S-1/A
|
|
10.46
|
|
08/19/2005
|
|
333-121173
|
|
|
|
|
|
|
10.31
|
|
Second Amended and Restated Research and License Agreement, dated July 22, 2009, between Fovea Pharmaceuticals SA and CombinatoRx, Incorporated.
|
|
8-K
|
|
10.1
|
|
07/23/2009
|
|
000-51171
|
|
|
|
|
|
|
10.32
|
|
Office and Laboratory Lease Agreement, dated as of October 18, 2005, by and between MA-Riverview, 245 First Street, L.L.C. and CombinatoRx, Incorporated.
|
|
S-1/A
|
|
10.48
|
|
10/24/2005
|
|
333-121173
|
|
|
|
|
|
|
10.33
|
|
First Amendment to Office and Laboratory Lease Agreement, dated as of March 9, 2006, by and between MA-Riverview, 245 First Street, L.L.C. and CombinatoRx, Incorporated.
|
|
10-K
|
|
10.44
|
|
03/20/2006
|
|
000-51171
|
|
|
|
|
|
|
10.34
|
|
Second Amendment to Office and Laboratory Lease Agreement, dated as of August 3, 2009, by and between MA-Riverview, 245 First Street, L.L.C. and CombinatoRx,
Incorporated.
|
|
8-K
|
|
10.1
|
|
08/04/2009
|
|
000-51171
|
|
|
|
|
|
|
10.35
|
|
Sponsored Research Collaboration Agreement, dated November 7, 2007, between Dart Therapeutics, LLC and CombinatoRx, Incorporated.
|
|
8-K
|
|
10.1
|
|
11/08/2007
|
|
000-51171
|
|
|
|
|
|
|
10.36
|
|
First Amendment to Sponsored Research Collaboration Agreement, dated as of October 20, 2008, between CombinatoRx, Incorporated, DART Therapeutics, LLC and GMT Charitable Research,
LLC.
|
|
8-K
|
|
10.1
|
|
10/22/2008
|
|
000-51171
|
|
|
|
|
|
|
10.37
|
|
Research Collaboration and License Agreement, dated as of May 1, 2009, by and between CombinatoRx, Incorporated and Novartis Institutes for BioMedical Research, Inc.
|
|
10-Q
|
|
10.43
|
|
05/11/2009
|
|
000-51171
|
|
|
|
|
|
|
10.38
|
|
Software License Agreement, dated as of May 1, 2009, by and between CombinatoRx, Incorporated and Novartis Institutes for BioMedical Research, Inc.
|
|
10-Q
|
|
10.44
|
|
05/11/2009
|
|
000-51171
|
|
|
|
|
|
|
10.39
|
|
Collaboration Agreement, dated August 11, 2009, by and between PGxHealth, LLC and CombinatoRx, Incorporated.
|
|
8-K
|
|
10.1
|
|
08/13/2009
|
|
000-51171
|
|
|
|
|
|
|
10.40
|
|
Asset Purchase Agreement, dated as of June 11, 2009, between Neuromed Development Inc. and Mallinckrodt Inc. and amendments thereto.
|
|
S-4/A
|
|
10.35
|
|
10/13/2009
|
|
333-161146
|
25
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Incorporated by Reference to:
|
Exhibit
No.
|
|
Description
|
|
Form or
Schedule
|
|
Exhibit
No.
|
|
Filing
Date
with
SEC
|
|
SEC File
Number
|
|
|
|
|
|
|
10.41
|
|
Development and Transition Services Agreement, dated as of June 11, 2009, by and among Neuromed Development Inc., Neuromed Pharmaceuticals Ltd. and Mallinckrodt Inc.
|
|
S-4/A
|
|
10.40
|
|
10/13/2009
|
|
333-161146
|
|
|
|
|
|
|
10.42
|
|
Agreement by and among Mallinckrodt Inc., a Covidien company, ALZA Corporation and Neuromed Pharmaceuticals Ltd. dated February 11, 2010.
|
|
10-Q
|
|
10.42
|
|
05/12/2010
|
|
000-51171
|
|
|
|
|
|
|
10.43
|
|
Sub-Lease Agreement between Neuromed Pharmaceuticals Inc. and Discovery Parks, Inc.
|
|
S-4/A
|
|
10.56
|
|
10/09/2009
|
|
333-161146
|
|
|
|
|
|
|
10.44
|
|
Sub-Lease Renewal and Amendment Agreement between Neuromed Pharmaceuticals Ltd. and Discovery Parks, Inc., dated as of November 2, 2009.
|
|
10-K
|
|
10.54
|
|
03/26/2010
|
|
000-51171
|
|
|
|
|
|
|
10.45
|
|
Lease Agreement between Neuromed Pharmaceuticals Inc. and Six Tower Bridge Associates.
|
|
S-4/A
|
|
10.57
|
|
10/09/2009
|
|
333-161146
|
|
|
|
|
|
|
10.46
|
|
Second Amendment to Lease Agreement between Neuromed Pharmaceuticals Inc. and Six Tower Bridge Associates, dated as of November 17, 2009.
|
|
10-K
|
|
10.56
|
|
03/26/2010
|
|
000-51171
|
|
|
|
|
|
|
10.47
|
|
Termination Agreement between CombinatoRx, Incorporated and Angiotech Pharmaceuticals, Inc., dated as of November 10, 2009.
|
|
8-K
|
|
10.1
|
|
11/10/2009
|
|
000-51171
|
|
|
|
|
|
|
10.48
|
|
Termination Agreement between CombinatoRx, Incorporated and Cystic Fibrosis Foundation Therapeutics, dated as of May 14, 2009.
|
|
8-K
|
|
10.1
|
|
05/20/2009
|
|
000-51171
|
|
|
|
|
|
|
21.1
|
|
List of subsidiaries.
|
|
10-K
|
|
21.1
|
|
03/26/2010
|
|
000-51171
|
|
|
|
|
|
|
*31.1
|
|
Certification of Chief Executive Officer pursuant to Exchange Act rules 13a-14 or 15d-14.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
*31.2
|
|
Certification of Chief Financial Officer pursuant to Exchange Act rules 13a-14 or 15d-14.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
*32.1
|
|
Certifications of Chief Executive Officer and Chief Financial Officer pursuant to Exchange Act rules 13a-14(b) or 15d-14(b) and 18 U.S.C. Section 1350.
|
|
|
|
|
|
|
|
|
|
Confidential treatment requested as to certain portions, which portions are omitted and filed separately with the Securities and Exchange Commission.
|
#
|
Management contract or compensatory plan or arrangement.
|
26
Combinatorx (NASDAQ:CRXX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Combinatorx (NASDAQ:CRXX)
Historical Stock Chart
From Apr 2023 to Apr 2024